Loading data for SLN — first visit, this takes a few seconds.

알림

Silence Therapeutics (SLN)

NasdaqGM: SLN · 실시간 가격 · USD

13.72

-0.25 (-1.79%)

종가 기준: Aug 14, 2026, 8:00 PM

-1.79% (1D)

데이터 없음

매수호가	n/a
시가총액	648.22M
매출 (ttm)	615K
순이익 (ttm)	-59.95M
베타	1.41
EPS (ttm)	-1.29
P/E (ttm)	n/a
선행 P/E	-17.93
P/B (ttm)	10.40
P/S (ttm)	1054.02
Earnings Date	Nov 5, 2026

매도호가	n/a
거래량	823,122
평균 거래량 (20일)	890,395
시가	14.01
전일 종가	13.97
일중 범위	13.44 - 14.22
52주 범위	4.19 - 17.58
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

SLN 소개

Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN36...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Sep 8, 2020

직원 수 88

상장 거래소 NasdaqGM

티커 SLN

웹사이트 https://www.silence-therapeutics.com

전체 기업 정보

재무 실적

2025년 Silence Therapeutics의 매출은 559K로, 전년 43.26M 대비 -98.71% 감소했습니다. 순이익은 -88.61M로, 95.57% 증가했습니다.

재무제표

어닝 서프라이즈

Silence Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:

매출 $422K 예상치 하회 $0, 및 197.18% 전년 대비 성장.

EPS -0.27 예상치 하회 -0.16, 및 50.91% 전년 대비 성장.

다음 실적 발표

Silence Therapeutics의 실적 발표 예정일은 Nov 5, 2026, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

5일 전 · MT Newswires

European Equities Traded in the US Rise in Thursday Trading

European equities traded in the US as American depositary receipts were higher late Thursday morning

5일 전 · Zacks

Wall Street Analysts Predict a 140.06% Upside in Silence Therapeutics (SLN): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 140.1% in Silence Therapeutics (SLN). While the effectiveness of this highly sought-after metric is questionabl...

1주 전 · MT Newswires

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday

1주 전 · MT Newswires

Silence Therapeutics' Divesiran Data Support Best-in-Class Potential, Morgan Stanley Says

Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activ

1주 전 · MarketBeat

Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial

Silence Therapeutics (NASDAQ:SLN) reported top-line results from its Phase II SANRECO trial of divesiran in patients with phlebotomy-dependent polycythemia vera, or PV, with the study meeting its prim...

2 페이지 중 1

Silence Therapeutics (SLN)